Skip to main content
Top
Published in: BMC Urology 1/2022

Open Access 01-12-2022 | Prostate Cancer | Research

Cholelithiasis increased prostate cancer risk: evidence from a case–control study and a meta-analysis

Authors: Ya-Dong Li, Zheng-Ju Ren, Liang Gao, Jun-Hao Ma, Yuan-Qing Gou, Wei Tan, Chuan Liu

Published in: BMC Urology | Issue 1/2022

Login to get access

Abstract

Introduction

Cholelithiasis represents a known risk factor for digestive system neoplasm. Few studies reported the association between cholelithiasis and the risk of prostate cancer (PCa), and the results were controversial.

Methods

We reviewed the medical records of the Second Affiliated Hospital of Chongqing Medical University Hospital to perform a retrospective matched case–control study, which included newly diagnosed 221 PCa patients and 219 matched controls. Logistic regression was applied to compare cholelithiasis exposure and adjusted for confounding factors. Additionally, we conducted a meta-analysis pooling this and published studies further to evaluate the association between cholelithiasis and PCa risk. Related ratio (RR) and 95% confidence interval (95%CI) were used to assess the strength of associations.

Results

Our case–control study showed that cholelithiasis was associated with a higher incidence of PCa (OR = 1.87, 95% CI: 1.06–3.31) after multivariable adjustment for covariates. The incidence of PCa was increased in patients with gallstones but not cholecystectomy. 7 studies involving 80,403 individuals were included in the meta-analysis. Similarly, the results demonstrated that cholelithiasis was associated with an increased risk of PCa (RR = 1.35, 95%CI: 1.17–1.56) with moderate-quality evidence. Cholelithiasis patients with low BMI increased the PCa incidence. Moreover, Subgroup analysis based on region showed that cholelithiasis was associated with PCa in Europe (RR = 1.24, 95%CI 1.03–1.51) and Asia (RR = 1.32, 95%CI 1.24–1.41).

Conclusions

The results suggested an association between cholelithiasis and the risk of PCa. There was no significant relationship between cholecystectomy therapy and PCa risk. Further cohort studies should be conducted to demonstrate the results better.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed
2.
go back to reference Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRef Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81.PubMedCrossRef
3.
4.
go back to reference Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, et al. Screening for familial and hereditary prostate cancer. Int J Cancer. 2016;138(11):2579–91.PubMedCrossRef Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, et al. Screening for familial and hereditary prostate cancer. Int J Cancer. 2016;138(11):2579–91.PubMedCrossRef
5.
go back to reference Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141–9.PubMedPubMedCentralCrossRef Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012;366(2):141–9.PubMedPubMedCentralCrossRef
6.
go back to reference Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, et al. Latent carcinoma of prostate at autopsy in seven areas The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977;20(5):680–8.PubMedCrossRef Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, et al. Latent carcinoma of prostate at autopsy in seven areas The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 1977;20(5):680–8.PubMedCrossRef
8.
go back to reference Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin North Am. 2010;39(2):157–69.PubMedCrossRef Stinton LM, Myers RP, Shaffer EA. Epidemiology of gallstones. Gastroenterol Clin North Am. 2010;39(2):157–69.PubMedCrossRef
9.
go back to reference Crawford RW, Rosales-Reyes R, Ramírez-Aguilar Mde L, Chapa-Azuela O, Alpuche-Aranda C, Gunn JS. Gallstones play a significant role in Salmonella spp. gallbladder colonization and carriage. Proc Natl Acad Sci U S A. 2010;107(9):4353–8.PubMedPubMedCentralCrossRef Crawford RW, Rosales-Reyes R, Ramírez-Aguilar Mde L, Chapa-Azuela O, Alpuche-Aranda C, Gunn JS. Gallstones play a significant role in Salmonella spp. gallbladder colonization and carriage. Proc Natl Acad Sci U S A. 2010;107(9):4353–8.PubMedPubMedCentralCrossRef
10.
11.
go back to reference Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. 2006;9(4):379–85.PubMedCrossRef Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. 2006;9(4):379–85.PubMedCrossRef
12.
go back to reference Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J. Incidence of cancer and statin usage–record linkage study. Int J Cancer. 2010;126(1):279–84.PubMedCrossRef Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J. Incidence of cancer and statin usage–record linkage study. Int J Cancer. 2010;126(1):279–84.PubMedCrossRef
13.
go back to reference Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008;123(4):899–904.PubMedCrossRef Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008;123(4):899–904.PubMedCrossRef
14.
go back to reference Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67(1):64–70.PubMedCrossRef Bhindi B, Locke J, Alibhai SMH, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67(1):64–70.PubMedCrossRef
15.
go back to reference De Nunzio C, Tema G, Lombardo R, Cicione A, Dell’’’’’Oglio P, Tubaro A. The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram. Minerva Urol Nefrol. 2020;72(6):729–36.PubMedCrossRef De Nunzio C, Tema G, Lombardo R, Cicione A, Dell’’’’’Oglio P, Tubaro A. The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram. Minerva Urol Nefrol. 2020;72(6):729–36.PubMedCrossRef
16.
go back to reference Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–8.PubMedCrossRef Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C, et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–8.PubMedCrossRef
17.
go back to reference Del S, Amante E, Fiori C, Alleva G, Alladio E, Marini F, Garrou D, Manfredi M, Amparore D, Checcucci E, et al. Prospective evaluation of urinary steroids and prostate carcinoma-induced deviation: preliminary results. Minerva Urol Nephrol. 2021;73(1):98–106. Del S, Amante E, Fiori C, Alleva G, Alladio E, Marini F, Garrou D, Manfredi M, Amparore D, Checcucci E, et al. Prospective evaluation of urinary steroids and prostate carcinoma-induced deviation: preliminary results. Minerva Urol Nephrol. 2021;73(1):98–106.
18.
go back to reference Zheng Y, Xu M, Li Y, Hruby A, Rimm EB, Hu FB, Wirth J, Albert CM, Rexrode KM, Manson JE, et al. Gallstones and risk of coronary heart disease: prospective analysis of 270 000 men and women from 3 US cohorts and meta-analysis. Arterioscler Thromb Vasc Biol. 2016;36(9):1997–2003.PubMedPubMedCentralCrossRef Zheng Y, Xu M, Li Y, Hruby A, Rimm EB, Hu FB, Wirth J, Albert CM, Rexrode KM, Manson JE, et al. Gallstones and risk of coronary heart disease: prospective analysis of 270 000 men and women from 3 US cohorts and meta-analysis. Arterioscler Thromb Vasc Biol. 2016;36(9):1997–2003.PubMedPubMedCentralCrossRef
19.
go back to reference Tavani A, Rosato V, Di Palma F, Bosetti C, Talamini R, Dal Maso L, Zucchetto A, Levi F, Montella M, Negri E, et al. History of cholelithiasis and cancer risk in a network of case-control studies. Ann Oncol. 2012;23(8):2173–8.PubMedCrossRef Tavani A, Rosato V, Di Palma F, Bosetti C, Talamini R, Dal Maso L, Zucchetto A, Levi F, Montella M, Negri E, et al. History of cholelithiasis and cancer risk in a network of case-control studies. Ann Oncol. 2012;23(8):2173–8.PubMedCrossRef
20.
go back to reference Li Q, Kuriyama S, Kakizaki M, Yan H, Nagai M, Sugawara Y, Ohmori-Matsuda K, Hozawa A, Nishino Y, Tsuji I. History of cholelithiasis and the risk of prostate cancer: the Ohsaki Cohort Study. Int J Cancer. 2011;128(1):185–91.PubMedCrossRef Li Q, Kuriyama S, Kakizaki M, Yan H, Nagai M, Sugawara Y, Ohmori-Matsuda K, Hozawa A, Nishino Y, Tsuji I. History of cholelithiasis and the risk of prostate cancer: the Ohsaki Cohort Study. Int J Cancer. 2011;128(1):185–91.PubMedCrossRef
21.
go back to reference Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
22.
go back to reference Yu ML. Association between screen-detected gallstone disease and cancer in a cohort study. Gastroenterology. 2017;153(5):1453.PubMedCrossRef Yu ML. Association between screen-detected gallstone disease and cancer in a cohort study. Gastroenterology. 2017;153(5):1453.PubMedCrossRef
23.
go back to reference Chen CH, Lin CL, Kao CH. Association between gallbladder stone disease and prostate cancer: A nationwide population-based study. Oncotarget. 2016;7(39):64380–9.PubMedPubMedCentralCrossRef Chen CH, Lin CL, Kao CH. Association between gallbladder stone disease and prostate cancer: A nationwide population-based study. Oncotarget. 2016;7(39):64380–9.PubMedPubMedCentralCrossRef
24.
go back to reference Kim TH, Lee SC, Kim WJ. Risk Factors for the Development of Prostate Cancer in Korean. Invest Clin Urol. 2004;45(10):1002–7. Kim TH, Lee SC, Kim WJ. Risk Factors for the Development of Prostate Cancer in Korean. Invest Clin Urol. 2004;45(10):1002–7.
25.
go back to reference Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, Franceschi S, La Vecchia C. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol. 2006;17(6):1014–7.PubMedCrossRef Bravi F, Scotti L, Bosetti C, Talamini R, Negri E, Montella M, Franceschi S, La Vecchia C. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol. 2006;17(6):1014–7.PubMedCrossRef
26.
go back to reference Cai H, Kong WT, Chen CB, Shi GM, Huang C, Shen YH, Sun HC. Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies. BMC Cancer. 2015;15:831.PubMedPubMedCentralCrossRef Cai H, Kong WT, Chen CB, Shi GM, Huang C, Shen YH, Sun HC. Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies. BMC Cancer. 2015;15:831.PubMedPubMedCentralCrossRef
27.
go back to reference Fan Y, Hu J, Feng B, Wang W, Yao G, Zhai J, Li X. Increased risk of pancreatic cancer related to gallstones and cholecystectomy: a systematic review and meta-analysis. Pancreas. 2016;45(4):503–9.PubMedCrossRef Fan Y, Hu J, Feng B, Wang W, Yao G, Zhai J, Li X. Increased risk of pancreatic cancer related to gallstones and cholecystectomy: a systematic review and meta-analysis. Pancreas. 2016;45(4):503–9.PubMedCrossRef
28.
go back to reference Chen CH, Lin CL, Kao CH. Association of cholecystectomy with the risk of prostate cancer in patients with gallstones. Cancers (Basel). 2020;12(3):544.CrossRef Chen CH, Lin CL, Kao CH. Association of cholecystectomy with the risk of prostate cancer in patients with gallstones. Cancers (Basel). 2020;12(3):544.CrossRef
29.
go back to reference Dong P, Flores J, Pelton K, Solomon KR. Prohibitin is a cholesterol-sensitive regulator of cell cycle transit. J Cell Biochem. 2010;111(5):1367–74.PubMedCrossRef Dong P, Flores J, Pelton K, Solomon KR. Prohibitin is a cholesterol-sensitive regulator of cell cycle transit. J Cell Biochem. 2010;111(5):1367–74.PubMedCrossRef
30.
go back to reference Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115(4):959–68.PubMedPubMedCentralCrossRef Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115(4):959–68.PubMedPubMedCentralCrossRef
31.
go back to reference Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, Solomon KR, Freeman MR. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 2007;67(13):6238–46.PubMedCrossRef Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, Solomon KR, Freeman MR. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 2007;67(13):6238–46.PubMedCrossRef
32.
go back to reference Freeman MR, Cinar B, Kim J, Mukhopadhyay NK, Di Vizio D, Adam RM, Solomon KR. Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids. 2007;72(2):210–7.PubMedCrossRef Freeman MR, Cinar B, Kim J, Mukhopadhyay NK, Di Vizio D, Adam RM, Solomon KR. Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids. 2007;72(2):210–7.PubMedCrossRef
33.
go back to reference Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68(15):6407–15.PubMedCrossRef Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68(15):6407–15.PubMedCrossRef
34.
go back to reference Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol. 2008;295(1–2):115–20.PubMedPubMedCentralCrossRef Dillard PR, Lin MF, Khan SA. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol. 2008;295(1–2):115–20.PubMedPubMedCentralCrossRef
35.
go back to reference Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.PubMedPubMedCentralCrossRef Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.PubMedPubMedCentralCrossRef
36.
go back to reference Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate. 2010;70(4):390–400.PubMedCrossRef Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate. 2010;70(4):390–400.PubMedCrossRef
37.
go back to reference Low-Beer TS, Nutter S. Colonic bacterial activity, biliary cholesterol saturation, and pathogenesis of gallstones. Lancet. 1978;2(8099):1063–5.PubMedCrossRef Low-Beer TS, Nutter S. Colonic bacterial activity, biliary cholesterol saturation, and pathogenesis of gallstones. Lancet. 1978;2(8099):1063–5.PubMedCrossRef
38.
go back to reference Wu T, Zhang Z, Liu B, Hou D, Liang Y, Zhang J, Shi P. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. BMC Genomics. 2013;14:669.PubMedPubMedCentralCrossRef Wu T, Zhang Z, Liu B, Hou D, Liang Y, Zhang J, Shi P. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. BMC Genomics. 2013;14:669.PubMedPubMedCentralCrossRef
39.
go back to reference Molinero N, Ruiz L, Milani C, Gutiérrez-Díaz I, Sánchez B, Mangifesta M, Segura J, Cambero I, Campelo AB, García-Bernardo CM, et al. The human gallbladder microbiome is related to the physiological state and the biliary metabolic profile. Microbiome. 2019;7(1):100.PubMedPubMedCentralCrossRef Molinero N, Ruiz L, Milani C, Gutiérrez-Díaz I, Sánchez B, Mangifesta M, Segura J, Cambero I, Campelo AB, García-Bernardo CM, et al. The human gallbladder microbiome is related to the physiological state and the biliary metabolic profile. Microbiome. 2019;7(1):100.PubMedPubMedCentralCrossRef
40.
go back to reference Rajagopala SV, Vashee S, Oldfield LM, Suzuki Y, Venter JC, Telenti A, Nelson KE. The human microbiome and cancer. Cancer Prev Res (Phila). 2017;10(4):226–34.CrossRef Rajagopala SV, Vashee S, Oldfield LM, Suzuki Y, Venter JC, Telenti A, Nelson KE. The human microbiome and cancer. Cancer Prev Res (Phila). 2017;10(4):226–34.CrossRef
41.
go back to reference Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta. 2006;1766(1):63–78.PubMed Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta. 2006;1766(1):63–78.PubMed
42.
go back to reference Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45–53.PubMedCrossRef Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45–53.PubMedCrossRef
44.
go back to reference Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(3):345–54.PubMedCrossRef Porter CM, Shrestha E, Peiffer LB, Sfanos KS. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(3):345–54.PubMedCrossRef
46.
go back to reference Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor–positive female breast cancer. J Natl Cancer Inst. 2016;108(8):undefined. Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor–positive female breast cancer. J Natl Cancer Inst. 2016;108(8):undefined.
47.
go back to reference Ozbek E, Otunctemur A, Dursun M, Sahin S, Besiroglu H, Koklu I, Erkoc M, Danis E, Bozkurt M. The metabolic syndrome is associated with more aggressive prostate cancer. Asian Pac J Cancer Prev. 2014;15(9):4029–32.PubMedCrossRef Ozbek E, Otunctemur A, Dursun M, Sahin S, Besiroglu H, Koklu I, Erkoc M, Danis E, Bozkurt M. The metabolic syndrome is associated with more aggressive prostate cancer. Asian Pac J Cancer Prev. 2014;15(9):4029–32.PubMedCrossRef
48.
go back to reference Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol. 2012;53(9):593–7.PubMedPubMedCentralCrossRef Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol. 2012;53(9):593–7.PubMedPubMedCentralCrossRef
49.
go back to reference Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013;111(7):1031–6.PubMedCrossRef Morote J, Ropero J, Planas J, Bastarós JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventós J, et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013;111(7):1031–6.PubMedCrossRef
Metadata
Title
Cholelithiasis increased prostate cancer risk: evidence from a case–control study and a meta-analysis
Authors
Ya-Dong Li
Zheng-Ju Ren
Liang Gao
Jun-Hao Ma
Yuan-Qing Gou
Wei Tan
Chuan Liu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2022
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-022-01110-8

Other articles of this Issue 1/2022

BMC Urology 1/2022 Go to the issue